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Research
AbstrACt
Aim The aim of this study was to inform thinking around 
the terminology for ‘schizophrenia’ in different countries.
Objectives The objective of this study was to investigate: 
(1) whether medical students view alternative terminology 
(psychosis subgroups), derived from vulnerability-
stress models of schizophrenia, as acceptable and less 
stigmatising than the term schizophrenia; (2) if there are 
differences in attitudes to the different terminology across 
countries with different cultures and (3) whether clinical 
training has an impact in reducing stigma.
Design This is a cross-sectional survey that examined the 
attitudes of medical students towards schizophrenia and 
the alternative subgroups.
setting The study was conducted across eight sites: 
(1) University of Southampton, UK; (2) All India Institute 
of Medical Science, India; (3) Rowan University, USA; (4) 
Peshawar Medical College, Pakistan; (5) Capital Medical 
University, China; (6) College of Medicine and Medical 
sciences, Bahrain; (7) Queens University, Kingston, Canada 
and (8) University of Cape Town, South Africa.
Method This study extended an initial pilot conducted 
by the Royal College of Psychiatrists on the term 
schizophrenia and psychosis subgroups to assess whether 
the subgroup terminology might have an effect on the 
attitudes of a convenience sample of medical students 
from eight different countries and potentially play a role in 
reducing stigmatisation.
results 1873 medical students completed a 
questionnaire recording their attitudes to schizophrenia 
and the psychosis subgroups. A reduction in negative 
perceptions were found for the psychosis subgroups, 
especially for the stress sensitivity psychosis and anxiety 
psychosis subgroups. Negative perceptions were found for 
drug-related psychosis. Participants who had undergone 
clinical training had overall positive attitudes. Differences 
across different countries were found.
Conclusion The attitudes towards psychosis subgroups 
used in this study have shown mixed results and 
variation across countries. Further research is warranted 
to investigate acceptability of terminology. Methods of 
reducing stigma are discussed in line with the findings.
Ethics The study received ethical approval from ERGO 
(Ethics and Research Governance Online; ID: 15972) and 
subsequently from the ethics committee at each site.
IntrODuCtIOn 
Although the term schizophrenia has been 
around for over 100 years, its use continues 
to generate controversy. Some argue that the 
term schizophrenia is semantically inexact, 
leading to the name being ‘essentially 
meaningless’.1 Brabban et al2 state that the 
term schizophrenia does more harm than 
good. They maintain that the lack of clear 
boundaries with other disorders in terms of 
symptoms, course, response to treatment or 
aetiology means that it has poor predictive 
power and utility. Experts have suggested that 
a lack of construct validity of the term schizo-
phrenia is demonstrated by its heterogeneity, 
strengths and limitations of this study
 ► A strength of the study is the large sample size. One 
thousand eight hundred and seventy-three medical 
students completed the questionnaire recording 
their attitudes to schizophrenia and the psychosis 
subgroups.
 ► The diverse sample that spans across eight different 
countries allows comparison of attitudes in different 
countries with different cultures.
 ► As the sample is large, it allows a good distribution 
of preclinical and clinical medical students in order 
to analyse the impact of clinical training on attitudes 
to schizophrenia.
 ► A limitation of the study is that it does not address 
other populations who are affected by the terminol-
ogy used with schizophrenia.
 ► A bias of the study is the use of a convenience 
sample.
 o
n
 4 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021461 on 7 June 2018. Downloaded from 
2 Rathod S, et al. BMJ Open 2018;8:e021461. doi:10.1136/bmjopen-2017-021461
Open Access 
where two people diagnosed with the same disorder can 
have completely different symptoms.1 3–6 Such variation 
in symptoms, without an agreed common cause, is there-
fore not helpful when predicting who will respond best to 
what treatments and the likely course of people’s experi-
ences. This heterogeneity can also explain why a propor-
tion of people are diagnosed with comorbid disorders as 
the symptom cluster can fit one disorder or another.1 2 
Since Bleuler7 first described the ‘group of schizophre-
nias’, there have been attempts to define the groups by 
consensus classification, for example, by WHO,8 the Amer-
ican Psychiatric Association9 and by research into symptom 
characteristics.10 11 The ICD-108 and DSM-IV-TR12 both 
describe paranoid, hebephrenic, undifferentiated, cata-
tonic and residual groups with simple schizophrenia only 
in ICD-10. However, these groupings have not been used 
much in research or clinical practice due to concerns 
about their validity, lack of predictive validity and stability 
over time.3 13–15 They have since been removed from the 
newest edition of the DSM-V.16 There remains a general 
agreement that patients who meet criteria for schizo-
phrenia according to current versions of DSM or ICD are 
a very diverse group.17 Symptom groupings have been 
successful at defining symptom clusters but not groups 
of patients, and it is argued that specific symptom-based 
approaches are more reliable and valid than a diagnostic 
approach.6
Psychological approaches to the difficulties associated 
with the term and concept of schizophrenia have tended 
to focus on using a symptom-based approach.6 This 
approach does not overcome the diversity of presenting 
patients, for example, with paranoia or abusive halluci-
nations. Alternative explanatory models of schizophrenia 
have been described cross-culturally, but these have not 
leant themselves directly to the development of diag-
nostic groupings. For example, culturally held attributes 
and beliefs relating supernatural powers or biology as the 
cause of symptoms does not readily transfer to a classifi-
cation system.18 19
In addition to clinical utility, another important aspect 
to consider would be how a diagnosis of schizophrenia 
has affected the people diagnosed and how useful the 
term is to those who receive it. Globally, the diagnosis of 
schizophrenia is associated with a high level of stigma.20 21 
For example, Howe et al22 found that people primarily 
experienced this diagnosis as a negative entity, without 
much utility beyond being able to access help. From a 
societal point of view, the diagnosis of schizophrenia 
can be highly stigmatising.23 It is associated with fear of 
violence, gradual deterioration and a lack of hope for 
recovery.13 21 24 25 A genetic explanation of schizophrenia 
has been found to be more frequently associated with stig-
matising attitudes as it relates to dangerousness, unpre-
dictability and people’s desire for social distance.26 Stigma 
can discourage people from seeking help early thereby 
delaying access to treatment27 28 and it also acts as a mech-
anism for social exclusion, hampering recovery29–31 and 
reducing employment and education opportunities.27 28
Patients can therefore prefer alternative terms like 
‘nervous breakdown’ which are imprecise but less stigma-
tising. Interestingly, the stigma of mental illness thrives 
in the medical profession as well. This can be attributed 
to the culture of medicine and medical training, percep-
tions of physicians and their colleagues, as well as the 
expectations and responses of healthcare systems and 
organisations.31 Lack of adequate knowledge on aetiology, 
curative treatments and clear outcomes from services also 
contribute.26
An approach to reducing the stigma related to the term 
schizophrenia has been achieved in Asian countries, for 
example, Japan, China and South Korea, by changing 
the name to a more meaningful term. As an example, 
Japan has changed the term schizophrenia to ‘integration 
dysregulation syndrome’ (togo-shitcho-sho) and its use is 
officially recognised.32 This new term refers to the vulner-
ability-stress model and emphasises that the disorder 
is treatable, with recovery possible if a combination of 
advanced pharmacotherapy and psychosocial interven-
tion is provided.33 It is experienced as more acceptable 
to patients and professionals.34 In South Korea, although 
the term was changed to johyeonbyung (‘attunement 
disorder’)35 mass media continue to use the old term 
schizophrenia.36
Developing terms which might be acceptable and mean-
ingful to both clinicians and patients would be a step 
forward in communication and treatment, impacting on 
engagement and outcomes. Kingdon et al have therefore 
described four subgroups of schizophrenia using termi-
nology developed with patients and informally tested with 
them and psychiatric staff.24 These psychosis subgroups 
are anxiety psychosis, drug-related psychosis, traumatic 
psychosis and stress sensitivity psychosis. These subgroups 
are based on a biopsychosocial, vulnerability-stress model 
of people’s experiences.1 They are formulation informed 
and derived from a cognitive–behavioural based under-
standing of schizophrenia. Kingdon and Turkington37 
hypothesise that common experiences leading up to the 
first episode of psychosis may be grouped into common 
pathways of people’s experiences. These subgroups have 
since been further explored and validated by Kingdon 
et al.1 3 14 24
The current study is an extension of the initial pilot24 
to assess whether the subgroup terminology might have 
an effect on the attitudes of a convenience sample of 
medical students from different countries, thereby poten-
tially reducing stigma in schizophrenia in the profession. 
The aim is to inform thinking around terminology and 
whether stigma can be reduced through this route.
AIM
The aim of this study was to:
1. Investigate whether medical students view alternative 
terminology, derived from vulnerability-stress models 
of schizophrenia, as acceptable and less stigmatising 
than the term schizophrenia itself.
 o
n
 4 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021461 on 7 June 2018. Downloaded from 
3Rathod S, et al. BMJ Open 2018;8:e021461. doi:10.1136/bmjopen-2017-021461
Open Access
2. Investigate if there are differences in attitudes to the 
different terminology across countries which may have 
varying cultures.
3. Investigate whether clinical training has an impact in 
reducing negative attitudes.
The primary hypothesis of this study was that the 
psychosis subgroups would be more acceptable and less 
stigmatising compared with the term schizophrenia 
among medical students in different countries with 
different cultures. Additionally, it was hypothesised that 
clinical training would reduce negative or stigmatising 
attitudes in medical students.
MEthOD
This study is an extension of the original pilot by Kingdon 
et al that used alternative terminology based on the 
psychosis subgroups. Kingdon et al24 examined the atti-
tudes of medical students towards schizophrenia and 
the alternative subgroups in a university in the UK. The 
current study, therefore replicates and expands on this 
work across seven additional countries.
study sites
The study was conducted across eight sites:
 ► University of Southampton, Southampton, UK.
 ► All India Institute of Medical Science, Delhi, India.
 ► Rowan University, New Jersey, USA.
 ► Peshawar Medical College, Peshawar, Pakistan.
 ► Capital Medical University, Beijing, China.
 ► College of Medicine and Medical sciences, Arabian 
Gulf University, Bahrain.
 ► Queens University, Kingston, Canada.
 ► University of Cape Town, Cape Town, South Africa.
study sample
Inclusion criteria
 ► All medical students throughout all years of under-
graduate medical training.
Exclusion criteria
 ► Those unwilling to participate.
Participants were medical students in years 1–5 (1–6 
in Bahrain) of medical schools from eight different 
countries. The views of medical students in years 1 and 
2 were compared with those in years 3–5, as participants 
in years 1 and 2 would not have been exposed to clin-
ical training in psychiatry or other clinical specialties 
(preclinical group). Participants in years 3–5 would have 
been exposed to clinical training in different specialties 
including psychiatry (clinical group). In Bahrain, years 1, 
2 and 3 are preclinical years and therefore we have used 
these 3 years for Bahrain as the preclinical group. The 
questionnaire was offered to all medical students.
The survey was conducted over the academic year 
2015–2016. Students were approached via lectures in 
their universities. Data collection forms were given a 
unique study number, protecting privacy and maintaining 
confidentiality. The database was prepared and analysed 
over the next 6 months. The results of this study are 
presented in aggregate form.
Questionnaire
The section of the Royal College of Psychiatrists’ ‘Every 
Family in the Land’ campaign questionnaire relating 
to schizophrenia20 was used for the study to replicate 
Kingdon et al24 study. The questionnaire asked the respon-
dents to ‘think of a person with schizophrenia’ and then 
rate eight characteristics on a 5-point Likert scale ranging 
from negative connotations to positive connotations of 
each characteristic. These characteristics covered: being 
dangerous to others; unpredictable; hard to talk to; have 
only themselves to blame; would not improve if given 
treatment; feel different from the way we all feel at times; 
will never recover fully and could pull themselves together 
if they wanted to. While formal psychometric properties 
of the scale have not been published, its validity could 
be said to have been established through the consensus 
process used in its development by the campaign. The 
students were also given brief descriptions of the psychosis 
subgroups and asked to rate them against the same char-
acteristics (online supplementary appendix).
Responses were scored from 1 to 5, with 1 representing 
most in agreement with the negative connotation of each 
statement; 3 being neutral and 5 being most in agree-
ment with the less negative connotation of the statement.
Patient and public involvement
As this study was an extension of the original pilot, 
patients were not involved in designing the question-
naire. However, they were involved in designing the ques-
tionnaire and design of the original pilot.
statistical analysis
Categorical data are presented as counts and percent-
ages. Response data are measured on a continuous scale 
and presented as bar charts showing the mean response 
value. For each of the eight characteristics, responses 
were modelled using a linear mixed-effects model with 
participant as a random effect. Age, gender, stage of study 
(clinical vs non-clinical), psychosis term and country as 
fixed effects. Missing values were excluded from the anal-
ysis. Statistical significance was assessed if p<0.05 and all 
statistical analyses were completed using R V.3.4.2.
Unlike previous analyses conducted in the Kingdon et 
al24 study, we opted to use a mixed-effects model as dichot-
omising the data into positive and negative responses 
causes a substantial loss of statistical power. Furthermore, 
adding all variables into one model allows adjustment for 
confounding factors while reducing the number of statis-
tical tests required.
In this study, we looked at a greater number of explan-
atory variables than the previous studies, including the 
effect of respondents’ country and clinical experience 
on their opinion, as well as age and gender. Therefore, it 
made sense to model the data using a regression model 
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adjusted for all factors together, rather than attempt 
presenting the data graphically or tabulated for each 
subgroup which would be lengthy and difficult to read.
rEsults
A total of 1873 medical students participated in the 
survey. Response rates were similar across all countries 
except the USA (n=126) and Canada (82). In order to 
achieve consistency in participant numbers, we have 
therefore grouped these two countries as North America 
for the analysis.
Demographics
Table 1 shows the demographics of the students from 
each country.
The demographics showed some differences across the 
countries sampled. The number of male respondents was 
much higher in India. Among the respondents, about 
76% of preclinical students in South Africa knew someone 
with schizophrenia whereas only 2% knew someone with 
schizophrenia in India. Understanding of schizophrenia 
in China was higher than that in the other countries. 
Overall, in all countries, the clinical group responded 
that they had a higher understanding of schizophrenia 
compared with preclinical group. In Bahrain, Pakistan, 
UK and South Africa, interest in psychiatry as a career was 
lower in the clinical years.
Acceptability of terminology
Table 2 shows results of the mixed-effects models.
Figure 1 illustrates the mean response scores, by 
country.
Overall, the results were found to be more positive 
towards sensitivity psychosis and anxiety psychosis. In 
relation to achievement of full recovery, participants had 
a particularly positive attitude towards anxiety psychosis. 
Participants responded with more negative views towards 
drug-related psychosis across several beliefs including 
dangerousness to others, hard to talk to, would not 
improve with treatment, feel different, could pull them-
selves together and have themselves to blame. Drug-related 
psychosis was also the only term viewed more negatively 
than schizophrenia for being ‘dangerous to others’. The 
psychosis subgroups were viewed more favourably than 
schizophrenia for ‘unpredictable’ and ‘will never recover 
fully’; anxiety psychosis the most favourably. However, 
all the psychosis subgroups were viewed more negatively 
than schizophrenia by the respondents for the charac-
teristics ‘only have themselves to blame’ and ‘could pull 
themselves together’.
The analysis showed that the age of the respondents 
did not have much of an impact on their opinion; it 
was found to be only significant for ‘could pull them-
selves together if they wanted to’ with a small effect size 
of +0.03 per year (older respondents less likely to agree). 
Male respondents were found more likely to agree with 
‘dangerous to others’, ‘have only themselves to blame’, T
ab
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‘feel different from the way we all feel at times’ (small 
effect size; −0.07 to −0.09 points). Gender did not show 
an effect on opinion on other statements.
Differences across countries
In general, students outside of UK reported a greater 
negative attitude towards all subgroups, except for ‘will 
never recover fully’ where the UK held a greater negative 
attitude. China, India, North America and South Africa 
reported a more positive attitude towards schizophrenia 
in the context of: ‘would improve with treatment’ and 
‘feel different to the way we all do at times’. USA and 
Canada had the most negative attitudes of schizophrenia 
in relation to: ‘dangerous to others’, ‘unpredictability’ 
and ‘hard to talk to’. Pakistan had the most negative atti-
tude for ‘only themselves to blame’ and ‘feel different 
from the way we all do’. China had the most negative atti-
tude on ‘could pull themselves together’.
Impact of clinical training
When comparing the preclinical years to respondents 
in clinical years, those in clinical years were less likely to 
have a negative view for all characteristics except ‘could 
pull themselves together’.
DIsCussIOn
The findings of the current study replicate those of 
Kingdon et al.24 They highlight more positive attitudes 
towards the psychosis subgroups, especially sensitivity 
psychosis and anxiety psychosis compared with schizo-
phrenia. This addresses the primary aim of the current 
study as it shows that such alternative terminology, derived 
from the vulnerability-stress models appears to be less 
stigmatising in the participant population. Drug-related 
psychosis is an exception, which similar to the previous 
study, remains associated with more negative attitudes. As 
a result of this study, the findings can now be generalised 
beyond the UK medical student population.
It is worth discussing why the drug-related psychosis 
subgroup was rated more negatively. It could be hypothe-
sised that the aetiology of this disorder may have an effect 
on participant’s views of it. That is, one may interpret that 
the person’s own behaviour (substance use) has resulted 
in the symptoms and a diagnosis of psychosis, so they 
are to blame. The perception that this disorder could be 
preventable compared with the other subgroups such as 
traumatic psychosis could lead to a more negative view of 
it. Further research would be useful in identifying if this 
is the cause of negative attitudes towards this subgroup so 
that these views can be influenced to reduce the stigma 
and improve clinical care. This is particularly important 
as evidence suggests that substance-induced psychosis, 
especially from cannabis, is significantly linked with 
later development of both bipolar affective disorder and 
schizophrenia.38
A strength of this study was its diverse sample that 
spans across eight different countries, thereby high-
lighting similarities and differences. While the psychosis 
Figure 1 Mean opinion score of five psychosis terms on a Likert scale of 1–5 among medical students from seven different 
localities. From darkest to lightest; schizophrenia, sensitivity psychosis, drug-related psychosis, traumatic psychosis, anxiety 
psychosis. 
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subgroups were viewed less negatively than schizophrenia 
in this study for many characteristics, many responses 
were broadly similar. For example, participants from all 
countries commonly responded that people across all 
groups ‘would be dangerous to others’; it was the degree 
of positivity or negativity that varied, with a few exceptions. 
Some differences in responses between participants of 
different countries could be attributed to cultural differ-
ences in explanatory models of illness. For instance, the 
UK students had more positive views of all terms except 
‘would improve with treatment’ and ‘feel different to the 
way we all do at times’ in comparison to the most negative 
attitudes in Pakistan for ‘only themselves to blame’ and 
‘feel different from the way we all do’. Culture influences 
beliefs around health and attributions to illness. Rathod 
et al in a previous study19 found key attributions around 
previous wrong doing, supernatural beliefs, social and 
biological factors in their sample of participants from 
South Asian Muslim and Balck African and African-Ca-
ribbean population with psychosis. McCabe and Priebe 
discussed that biological explanations were much more 
frequently cited by Caucasians than African-Caribbean 
and West Africans when describing symptoms of mental 
illness.39 Attributions to illness influence help seeking 
pathways into care and clinicians attitudes towards care as 
well. This understanding can help to improve care.
In this study, those in clinical years were less likely to 
have a negative view for all characteristics except ‘could 
pull themselves together’. It is possible that clinical 
training has an impact on attitudes and this can be capi-
talised on further. The responses can be used to develop 
tailored teaching programmes in individual countries 
to address the issues and dispel some of the myths and 
misguided perceptions held about the condition.
Given that less than 50% of the students in each country 
expressed a wish to pursue a career in psychiatry, it is 
worth exploring further whether their negative attitudes 
towards schizophrenia (possibly other mental health 
disorders and the specialty) has an influence on this deci-
sion. If this is indeed found to be the case, addressing 
the stigma attached to schizophrenia (and possibly other 
mental health conditions) either through better informa-
tion and training, or renaming it using these subgroups 
may influence more students to consider a career in 
psychiatry. The current study has started the process of 
exploring what options may be preferable or less stigma-
tising to improve our general understanding.
When looking at ways to reduce stigma in medical 
students, it may be important to note that low numbers of 
participants have reported knowing someone with schizo-
phrenia in the current study. Maulik et al40 concluded that 
the best antistigma interventions are those that involve 
face-to-face contact with someone with the mental health 
diagnosis. Any future education programmes may benefit 
from involving people with lived experience in any 
teaching or training programmes.
Some may argue that the benefits of renaming schizo-
phrenia outweigh the disadvantages.41 Lasalvia et al41 
draw their conclusion mainly from the outcomes of 
renaming schizophrenia in Asian countries. They argue 
that changing the name can help to promote the provi-
sion of interventions and improve the public image of 
both the disorder and of those diagnosed with it. Such a 
name change as a move to the psychosis subgroups may 
also be welcomed by researchers as it may encourage the 
study of interventions specifically for the subgroups as 
opposed to schizophrenia as a whole. This may lead to 
better outcomes and a quicker access to the right treat-
ment for the specific symptoms of the different psychosis 
subgroups.
One must be cautious, however, as a recent review of 
the literature has shown that only one longitudinal study 
has so far been conducted to investigate the impact of 
renaming schizophrenia.42 Therefore, a longitudinal 
study may be necessary to identify the effects over time, 
particularly in countries where this has not already 
happened. Bentall43 states that merely changing the 
name of schizophrenia is unlikely to have a marked effect 
because any reduction in negative stigma is likely to be 
short lived.
Our group acknowledges this argument and under-
stands that currently there is insufficient evidence that 
these subgroupings are likely to be adopted clinically. 
However, we argue that there are benefits in pursuing 
further research in this area due to the potential advan-
tages and possibility of future classification modifi-
cations based on aetiology. Additionally, the results 
of this and other similar surveys has implications in 
understanding what aspects of the condition influ-
ence the participants attitudes towards the profession 
and providing care. The acceptability of the subgroups 
also provides an opportunity to use these explanatory 
models of illness in discussions with patients to engage 
them in a meaningful way, incorporating their cultural 
dispositions and thereby improving outcomes. Explana-
tory models, despite placing some emphasis on general 
beliefs, are constructed and connected in order to 
respond to specific aspects of illness.
Although the current study has improved the external 
reliability of a previous study in a larger and more 
generalisable population, it fails to address the views of 
other populations who are affected by the terminology 
used with schizophrenia. Kingdon et al1 24 showed that 
patients with schizophrenia and their family members 
preferred the subgroups compared with the term 
schizophrenia. However, this was only conducted in a 
small UK sample. The current study would have bene-
fitted from including participants from different groups 
including patients and family members in order to be 
able to generalise the findings from the previous study 
to these participant groups as well.
Another limitation of the study is the convenience 
sample. While the questionnaires were offered to all the 
medical students in the stated year, only those who chose 
to respond did so. Therefore, it was a self selected and 
convenience sample. This also dictated the sample size.
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In conclusion, this study explores whether alternative 
terminology using subgroups based on the biopsycho-
social model is more acceptable than the term schizo-
phrenia. While currently this terminology is less likely 
to be adopted, it is possible that in the future alterna-
tive terminology is considered and the process of eval-
uation as we have started would provide the evidence. 
The psychosis subgroups used in this current study have 
shown mixed results and variation across countries. 
Further research is warranted to investigate accept-
ability of terminology and association of attitudes 
towards those who are diagnosed with schizophrenia 
and their carers.
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